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1. Introduction 
Acute leukemia is characterized by abnormal proliferation, inhibition of differentiation and 
expansion of leukemic cells blocked at the early stage of hematopoiesis. Acute myeloid 
leukemia (AML) is a malignant hematological disease of hematopoietic precursor cells of 
non-lymphoid lineage. Recent insights into the molecular mechanisms of AML are 
challenging the traditional diagnostic classification, prognostic significance and clinical 
practice of this hematological disorder.  
1.1 Concept and classification 
AML is a clinically heterogeneous disorder with distinct clinical and biological features. 
Until the 1970s, diagnosis was based on morphological examination of bone marrow and 
peripheral blood samples. In 1976, French, American, and British hematologists (the FAB 
group) defined six subgroups of AML morphological variants (Bennett et al., French-
American-British Cooperative Group [FAB], 1976). This classification allowed us to identify 
several types of AML:  M1-M6. Blastic populations were identified using standard staining 
techniques and consequently classified depending on reactivity to certain cytochemicals, 
namely, myeloperoxidase and Sudan black B (markers of myeloid differentiation) and 
nonspecific esterase reactions such as alpha-naphthyl acetate esterase and alpha-naphthyl 
butyrate esterase  (for monocytic lineage). Later on, this group identified two new types of 
AML (M0 and M7) according to cytochemical and inmunophenotypical features (Bennett et 
al., FAB, 1985). Over the past decade, refinement in the diagnosis of subtypes of AML and 
advances in therapeutic approaches have improved the outlook for patients with AML 
(Döhner et al., 2010).  
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FAB classification 
M0: AML minimally differentiated 
M1: AML without maturation 
M2: AML with maturation 
M3: Acute promyelocytic leukemia  
M4: Acute myelomonocytic leukemia 
M5: Acute monoblastic leukemia 
M6: Acute erythroleukemia 
M7: Acute megakaryoblastic leukemia 
Table 1. FAB classification of acute myeloid leukemia (AML). 
Since several specific cytogenetic and genetic abnormalities in AML are associated with a 
characteristic morphology and have distinctive clinical behavior (Harris et al., World Health 
Organization [WHO], 1999). The World Health Organization (WHO), classification of 
myeloid neoplasms and acute leukemias integrates genetic, clinical data, and morphological 
features. 
Three prognostic groups have been described classically according to cytogenetic findings. 
The favorable prognostic group includes the following chromosomal abnormalities:  
t(15;17), t(8;21) and inv(16). Normal karyotype and cytogenetic abnormalities not classified 
as favorable or adverse comprise the intermediate group. The adverse prognosis group 
includes patients with complex karyotype, del (5q), 5 or 7 monosomy, 3q abnormalities and 
t(6;9) (Dohner et al., 2010). 
Recently the WHO published a revised and updated edition of the 1998 WHO classification 
where the importance of gene mutations as diagnostic and prognostic markers in myeloid 
neoplasms was acknowledged. This group recommended that fluorescence in situ 
hybridization (FISH), reverse transcriptase–polymerase chain reaction (RT-PCR) and 
mutational status studies should be guided through clinical, laboratory, and morphologic 
information. Mutational studies for mutated NPM1, CEBPA, FLT3, KIT, WT1, and MLL are 
recommended in all cytogenetically normal AML. Table 2 lists the major subgroups of AML 
in the WHO classification (WHO, 2009). 
The genes involved in the pathogenesis of leukemia are normal genes (proto-oncogenes) 
with either structural alterations or deregulated expression patterns, which generates in turn 
a novel gene (an oncogene) whose protein product acts on the host cell to enhance 
malignancy-related characteristics. Oncogene activation and the loss of tumor-suppressor 
genes are consistently associated with some types of leukemia (Cline, 1994). Some of the 
molecular alterations involved in the pathogenesis of AML are: translocations, mutations 
and overexpression of normal genes, which often characterizes a particular subtype of AML. 
Therefore, there are also activating mutations which lead to increased proliferation or 
survival, or both, of haematopoietic progenitor cells through the stimulation of tyrosine 
kinases such as FLT3 or RAS family members. These are considered class I mutations 
(Haferlach et al., 2007; Schlenk et al., 2008). Class II mutations interfere with transcription 
and lead to a maturation arrest either through a direct alteration of transcription factors due 
to gene fusions (CBF-leukemias or PML-RARA positive leukemia) or by indirect 
interference with transcription (MLL-rearrangements). Cytogenetic and molecular analysis 
of leukemic blasts, provide critical diagnostic, therapeutic and prognostic information.  
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Acute myeloid leukemia with recurrent genetic abnormalities
 AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 
 AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
 APL with t(15;17)(q22;q12); PML-RARA 
 AML with t(9;11)(p22;q23); MLLT3-MLL 
 AML with t(6;9)(p23;q34); DEK-NUP214 
 AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
 AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 
 Provisional entity: AML with mutated NPM1 
 Provisional entity: AML with mutated CEBPA 
Acute myeloid leukemia with myelodysplasia-related changes 
Therapy-related myeloid neoplasms 
Acute myeloid leukemia, not otherwise specified 
 AML with minimal differentiation 
 AML without maturation 
 AML with maturation 
 Acute myelomonocytic leukemia 
 Acute monoblastic/monocytic leukemia 
 Acute erythroid leukemia 
  Pure erythroid leukemia 
  Erythroleukemia, erythroid/myeloid 
Acute megakaryoblastic leukemia 
Acute basophilic leukemia 
Acute panmyelosis with myelofibrosis 
Myeloid sarcoma 
Myeloid proliferations related to Down syndrome 
 Transient abnormal myelopoiesis 
 Myeloid leukemia associated with Down syndrome 
Blastic plasmacytoid dendritic cell neoplasm
Table 2. WHO classification of acute myeloid leukemia and related neoplasms. 
1.2 Molecular markers 
1.2.1 Useful at diagnosis and to evaluate Minimal Residual Disease (MRD) 
Molecular techniques allow us to diagnose and classify AML, establishing groups of 
patients with different disease behaviour and prognosis.  In the same way, the development 
of more specific therapies and the application of risk-adjusted therapeutic approaches have 
been made possible. Disease relapse can be favored by persistent low numbers of leukemic 
cells undetectable by conventional techniques. Monitoring of AML patients has given rise to 
a higher insight into the effectiveness of treatment. At diagnosis, some types of myeloid 
leukemias display a molecular change that might be useful as a marker of neoplastic disease 
and MRD (Hilden et al., 1995; Nakao et al., 1996; Foroni et al., 1999; Lo Coco et al., 1999a). 
Specific molecular alterations of certain hematologic malignancies are useful in the detection 
of MRD. Translocations are the most widely involved chromosomal abnormalities in AML. 
These can give rise to an altered function or activity of oncogenes located at or near the 
translocated breakpoint. The first molecular cytogenetic marker described in AML was  
t(15;17), which originates a single morphologic phenotype (hyper- or micro-granular 
French-American-British [FAB] AML-M3 acute myeloid leukemia) (Bernstein et al., 1980). 
This rearrangement disappears with complete remission and is able to predict a relapse very 
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accurately. The presence of this translocation or its fusion gene (PML/ RAR) is thus a 
detectable tumor marker in leukemic cells, which allows assessment of the molecular 
response to therapy in AML-M3 patients (Lo Coco et al., 1999b). RUNX1-RUNX1T1 and 
CBF-MYH11 are other genetic alterations less likely to predict relapse, since they may 
persist even when complete remission (CR) has been achieved. However, the applicability of 
this strategy has been limited to those leukemia subsets characterized by genetic markers. 
Recent interest has focused on identifying new molecular markers that might prove 
significant in the diagnosis and follow-up of MRD in AML patients. In recent years, a 
variety ot potential molecular markers have been identified (see table 2 and table 3) (Radich 
& Thomson, 1997; Inoue et al., 1994; Kreuzer et al., 2001; Alberta et al., 2003; Lin et al., 2005; 
Gilliland & Griffin, 2002; Morishita et al., 1992).  
 
Involvement of transcription 
 Prevalence Prognostic value 
Associated
mutations
Utility in MRD 
CBF-leukemias: 
Inv 16/t(16;16) 
CBFB/MYH11 
t(8;21);RUNX1-
RUNX1T1 
15% 
Favorable (Poor 
with KIT in 
normal karyotype 
leukemia) 
FLT3 
NRAS  
KIT  
Possible 
PML-RARA 10-15% Favorable FLT3 (40%) Yes
MLL mutation 10-30% Poor - Yes
CEBPA mutation 15-20% 
Favorable if 
biallelic
- Yes 
AML1 mutation 1-20% Poor 
FLT3 (in 20% 
M0)
Yes 
Activating mutations
FLT3-ITD  
mutation 
28-34% Poor  Possible 
FLT3-TKD 
mutation 
20-30% Controversial CBF, NPM1  
c-KIT mutation 6-48% Poor CBF-leukemias Yes
RAS mutation  
NRAS 11%
KRAS 5%
Not influence  
FLT3-ITD (24-
26%)
- 
Other genes alterations
NPM1 mutation 35% 
Favorable 
(without FLT3)
FLT3 Yes 
BAALC 
overexpression 
65% Poor - Possible 
EVI-1 
overexpression 
10-22% Poor - Possible 
WT1 
overexpression 
10-15% Poor - Yes 
DNMT3A 
mutation 
20% Poor FLT3-ITD - 
IDH1/2 mutation 15% Controversial NPM1, FLT3-ITD -
Table 3. Molecular markers in AML: prevalence, prognostic, associated mutations, genetic 
alterations and utility in MDR. 
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1.2.2 Genetic alterations with prognosis value 
In recent years, the availability of new genetic and molecular prognostic markers in AML 
has grown considerably. This is particularly important in the case of patients with normal 
cytogenetics who comprise the largest subgroup of AML patients (approximately 45%) 
where many new prognostic factors have been identified. These include gene mutations in 
FLT3 (Fms-like tyrosine kinase 3; generally FLT3-ITD has been associated with significantly 
worse survival (Sheikhha et al, 2003)), NPM1 (nucleophosmin 1) and CEBPA (CCAAT 
enhancer-binding protein-α; generally favorable in cases of biallelic mutations) and gene 
overexpression as BAALC, WT1, EVI1 and MN1 (Foran, 2010).  
Identifying alterations in these genes might provide independent prognostic value in 
predicting the outcome of acute leukemia, as in the case of the NPM1 mutation gene, which 
is a relatively frequent abnormality in AML patients and is useful in detecting MRD (Falini 
et al., 2007). 
2. Detailed description of molecular markers 
Next, we will describe the most common molecular markers in AML.  
2.1 Core Binding Factor (CBF) 
Leukemias affecting CBF are characterized by rearrangements of genes that code for 
components of the heterodimeric transcription factor CBF, which plays an essential role in 
haematopoiesis (Gabert et al., 2006). CBF complex is a heterodimer composed of RUNX1 
(also called AML1) and CBF and is the target of at least three common transloctions in 
AML: t(8;21)/RUNX1-RUNX1T1, t(3;21)/RUNX1-EVI1 and inv(16) or t(16;16) resulting in 
CBF-MYH11. Rearrangements of AML1 and CBFB with other genes lead to chimeric 
proteins that disrupt the CBF complex, suppressing the activation of transcription.  
2.1.1 AML1 (RUNX1) rearrangements 
AML1, also called, RUNX1, is normally expressed in all hematopoietic lineages and 
regulates the expression of several genes specifically linked to hematopoiesis, including the 
granulocyte colony-stimulating factor receptor, interleukin 3, T-cell receptor, and 
myeloperoxidase (MPO) genes. The AML1 gene (on 21q22) is one of the genes most 
frequently deregulated in leukemias, generally through translocations that produce chimeric 
messenger RNA. Chimeric protein AML1-ETO (RUNX1-RUNX1T1) results from the 
t(8;21)(q22;q22) involving the AMLI gene on chromosome 21 and the ETO gene on 
chromosome 8. This rearrangement is detected in approximately 8% of AML cases in 
children and young adults. RUNX1-RUNX1T1 is a marker for favourable outcome and an 
important PCR target for MRD detection. Most patients achieve a CR after induction 
therapy and those patients benefit most from a postremission therapy with high-dose 
cytarabin (Bloomfield et al., 1998; Perea et al., 2006). Hence, this marker permits to single out 
a relatively small subgroup of patients who are more likely to relapse (Gabert et al., 2003). 
RUNX1-RUNX1T1 is also frequently associated with c-kit mutations which determine an 
adverse outcome within this group of patients with favorable prognosis. In addition, the 
loss of Y chromosome in male patients with t(8;21) leukemia is a negative prognostic factor 
for the overall survival (Schlenk et al., 2004). While the molecular diagnosis is performed by 
qualitative and quantitative Real Time RT-PCR (QRT-PCR), MRD monitoring is performed 
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by quantitative QRT-PCR. The rare balanced t(3;21)(q26;q22) was described in AML, mainly 
after treatment with topoisomerase II inhibitors. This translocation fuses the AML1 gene on 
21q22 and the EVI-1 gene on 3q26 resulting in t(3;21)(q26;q22). This translocation is 
associated with higher WBC and platelets counts but is not, however, predictive for relapse-
free or overall survival (Preudhomme et al., 2000; Meyers et al., 1993; Lutghart et al., 2010). 
2.1.2 AML1 mutations 
AML1 mutations can be found in de novo leukemia, particularly subtypes FAB M0 and M7, 
as well as in patients with trisomy 21 and myelodysplastic syndromes. Testing for mutations 
can be performed By real time PCR or PCR-single stranded conformational polymorphism 
(SSCP). A multivariate analysis carried out by Schnittger et al., showed an independent 
unfavourable prognostic significance of AML1 (or RUNX1) mutations for overall survival 
(Schnittger et al., 2011). 
2.1.3 CBFb-MYH11 
Inv(16)(p13;q22) or t(16;16)(p13;q22) are among the most frequent recurring chromosomal 
rearrangements detected in AML, generally observed in cases showing myelomonocytic 
differentiation and having abnormal bone marrow eosinophils (M4 Eo AML in the French 
American British (FAB) classification). Inv(16)(p13;q22) is found in approximately 10-12% of 
cases of AML. It can occur in all age groups but is predominantly seen in younger patients. 
This rearrangement results in the disruption of the myosin heavy chain (MYH) gene at 16p13 
and the core binding factor (CBF) gene at 16q22 (FAB, 1976). Ten different CBF-MYH11 
transcripts have been reported, but the frequency of each transcript is variable. CBFB-MYH11 
positive patients are considered to have a favourable prognosis. This rearrangement is 
frequently associated with c-kit and FLT3 mutations which worsen the prognosis. Quantitative 
QRT-PCR allows monitoring of CR (Gabert et al., 2003; Perea et al., 2005). 
2.1.4 CEBPA 
The CCAAT/enhancer binding alpha protein (C/EBP) is the founding member of a family 
of related leucine zipper transcription factors. Mutations in CEBPA are found in 5-14% of 
AML and have been associated with a relatively favourable outcome only in biallelic 
mutations of this gene. There are two main classes of mutation situated at the N- terminal or   
 
 
Fig. 1. Schematic representation of CEBPA (by Smith, 2004). 
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C-terminal basic leucine zipper (bZIP) regions (Figure 1). The latter affect both DNA binding 
and homo and heterodimerization with other CEBP-proteins. The former introduce a 
premature stoppage of the translation of the p42 CEBPA protein, preserving a p30 isoform, 
which was shown to inhibit DNA binding and transactivation by C/EBPpCEBPA 
mutations are exclusively related to the intermediate risk group karyotype AML. CEBPA 
insertion, deletions and point mutations are detected usually by DNA sequencing (Wouters 
et al., 2009; Pabst et al., 2001; Fuchs et al., 2008).  
2.2 PML-RAR 
Acute promyelocytic leukemia is a distinct subtype of AML (AML-M3) according to the FAB 
classification. AML-M3 is characterized by t(15;17) that involves the retinoic acid receptor a 
(RAR) gene on chromosome 17 and the promyelocytic leukemia gene (PML) on 
chromosome 15. At the molecular level, t(15;17) results in a hybrid PML/ RAR gene, which 
is easily identified by reverse transcriptase-polymerase chain reaction (RT-PCR).  This test 
provides a rapid and refined diagnosis. The usefulness of minimal residual disease 
monitoring during follow up (Lo Coco et al., 1992; Lo Coco et al., 1999a) has been well 
established. The different breakpoints within the PML gene cluster can be located in three 
regions: bcr1, 2 and 3. 
The assessment of remission status at the molecular level by RT-PCR of PML-RAR 
represents a significant clinical advance with respect to other poorly sensitive methods 
(morphology, karyotype). The treatment of this disease (arsenicals, liposomal ATRA, other 
retinoid derivatives, etc) needs to be assessed taking into account the response at the RT-
PCR level. The detection of residual PML-RAR transcripts during clinical remission 
predicts subsequent hematologic relapse. This determines the need for additional treatment 
given the benefits of anticipating salvage therapy in AML-M3. Figure 3 shows the 
statistically significant difference between patients treated for molecular relapse and the 
historical series treated for hematologic relapse (Lo Coco et al., 1999b). 
 
 
Fig. 2. Kaplan-Meier estimates of overall survival from relapse in patients treated at the time 
of molecular relapse (dotted line) and in the historical series of patients treated for 
hematologic relapse (continuous line). 
Around 40% of all cases of PML-RAR-positive AML show FLT3 mutations. FLT3-ITD 
mutations, but not FLT3-D835, are associated with characteristic diagnostic hematological 
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features of acute promyelocytic leukemia, in particular with high WBC counts. Also, FLT3 
mutations, especially ITD, can adversely affect overall survival and disease-free survival in 
PML-RAR-positive AML (Beitinjaneh et al., 2010). However, in a large series of 739 
patients with acute promyelocytic leukemia treated with ATRA and anthracycline-based 
chemotherapy, we were unable to demonstrate an independent prognostic value of FLT3 
mutations (Barragan et al., 2011).  
2.3 DEK-CAN 
AML defined by t(6;9) is a relatively rare disease, associated with specific clinical and 
morphological features (Garcon et al., 2005). Especially in young adults, the leukemic phase 
can be preceded by dysplastic features, conferring a bad prognosis. Morphological findings 
usually correlate with FAB M2 (60%), M4 (30%), or Ml (von Lindern et al., 1990). A chimeric 
protein is generated, resulting from the fusion between DEK and the 30- terminus of the 
CAN gene, also known as NUP214 (von Lindern et al., 1990). DEK is a component of 
metazoan chromatin capable of modifying the structure of DNA by introducing supercoils. 
CAN is a nuclear pore complex protein implicated in nucleocytoplasmic trafficking.  The 
CAN gene is also involved in several fusion transcripts described in acute leukemia other 
than DEK in t(6;9)(p23;q34) AML, such as the SET gene and recently with ABL in T-cell 
acute lymphoblastic leukaemia (ALL). The DEK-CAN transcript can be used as a marker of 
t(6;9) AML which can be sensitively monitored by the polymerase chain reaction. This offers 
a great advantage in the diagnosis, monitoring of response to chemotherapy, and detection 
of minimal residual disease after bone marrow transplantation (von Lindern et al., 1992). 
DEK-CAN is related with an adverse prognosis (Dohner et al., 2010). 
2.4 NPM1 
NPM1 gene is located in 5q35 and encodes a phosphoprotein, nucleophosmin, which moves 
between the nucleus and the cytoplasm. The gene product is thought to be involved in 
several processes including regulation of the ARF/p53 pathway. Mutations in exon 12 in 
this gene are associated with AML with normal karyotype (50%) and especially correlate 
with monocytic leukemias. Patients with NPM1 mutations have a significantly higher rate of 
complete remissions (CRs) after standard induction chemotherapy except for cases 
associated with internal tandem duplications mutations of FLT3 (Falini et al., 2007; Gale et 
al., 2008). Gale et al. (2008) identified 3 prognostic groups among the NPM1+ AML patients: 
good in those with only a NPM1 mutation and absence of a FLT3-ITD; intermediate in those 
with either absence of FLT3-ITD or NPM1 mutations or mutations in both genes; and poor 
in those with only FLT3-ITD. Monitoring can be performed by quantitative PCR (Schnittger 
et al., 2009). In our group, the incidence of NPM1 mutation was 30% (17 of 55 patients with 
AML), being this prevalence similar to that found for FLT3-ITD in the same population (29 
%). The 17 NPM1+ AML patients were distributed as follows: eight M1-M2 (47.1 %), four 
M4-M5 (23.5%), and five not labelled (29.4 %) because cytogenetic studies were not 
informative due to several reasons.  64.7% of the NPM1+ patients had a normal karyotype, 
while 5.8% of them had cytogenetic anomalies. FLT3-ITD mutations were found in 41.2 % of 
the NPM1+ AML cases. In contrast to what has been described in the literature our group 
did not find a higher incidence of M4 or M5 subtypes (Thiede et al., 2002). In our case, a 
higher incidence of M1 and M2 subtypes was detected (Table 4). However the differences 
are most likely attributable to the small sample size of our cohort as compared to the Thiede 
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cohort. The global mortality was analyzed disregarding risk factors, with a mortality of 67 % 
in the NPM1+/FLT3-ITD- group standing in clear contrast to a 100% death rate in the 
NPM1+/FLT3-ITD+ group (Lopez Jorge et al., 2006). This was confirmed in another study 
where we analysed the incidence and prognostic relevance of CD34/CD7/DR surface 
markers in a group of forty two NPM1positive patients and related it to FLT3-ITD 
mutations. We found that 84% of the NPM1 positive patients had normal karyotypes. 
Mutations in FLT3-ITD were detected in 23.8% of the NPM1+ patients. The screening for 
this mutation could be very useful in the future as patients with normal karyotype and 
expression of this molecular marker is included in a better prognostic subgroup (Gomez 
Casares et al., 2009; Dohner et al., 2010). 
 
 Nº patients NPM1+ NPM1- 
Patients (%) 55 17 (30.9) 38(69) 
Median (range age) (years) 60 (18-95) 58 (18-82) 60 (19-95) 
Age, rFAB subtype 
M0 
M1/M2 
M4/M5 
M6 
Not labeled 
 
5 
8/10 
12/4 
1 
15 
 
0 
4/4 
3/1 
0 
5 
 
5 
4/6 
9/3 
1 
10 
Cytogenetic: 
Normal karyotype 
del(5) 
del(7) 
trisomy 8 
t(4;11) 
t(8;21) 
t(10;11) 
t(9;11) 
t(12;13) 
t(3;10) 
+11 
-Y 
Complex: >3 abnormalities 
Non determinated 
 
24 
2 
5 
1 
1 
2 
1 
1 
1 
1 
2 
2 
2 
14 
 
11 
0 
0 
1 
0 
0 
0 
0 
0 
0 
0 
0 
0 
5 
 
13 
2 
5 
0 
1 
2 
1 
1 
1 
1 
2 
2 
2 
9 
FLT3-ITD+ (%) 16 (29) 7(41.2) 9(23.6) 
Table 4. Cytogenetics and demographic characteristics in a group of 55 AML patients (Lopez 
Jorge et al., 2006). 
2.5 c-KIT 
KIT is a proto-oncogene located on chromosome band 4q11-12 and encodes a 145-kDa 
transmembrane glycoprotein member of the type III receptor tyrosine kinase family. Ligand 
independent activation of KIT results from mutations in the extracellular portion of the 
receptor (exon 8), transmembrane and juxtamembrane domains (exons 10 and 11, 
respectively), and activation loop of the tyrosine kinase domain (exon 17). c-KIT mutations 
have been found in a variable but relatively high frequency (up to 50%) in patients with CBF 
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AML, including both t(8;21) and the other major type of CBF AML inv(16)(p13q22) or 
t(16;16)(p13;q22). This appears to confer a quite unfavourable prognosis with higher relapse 
risk (associated to inv(16) or t(8;21)). An adverse effect on OS in AML with inv(16) has been 
described, particularly those that occur in exon 17 (Paschka et al., 2006). Such patients may 
warrant more aggressive or alternative therapy. The presence of the c-KIT mutation would 
be also important because it provides a target for novel tyrosine kinase inhibitor (TKI) 
therapy (Pollard et al., 2010).  
2.6 FLT3 
Flt3 is a member of the class III tyrosine kinase receptor family that includes the c-kit, c-fms, 
and PDGF receptors. The Flt3 receptor is preferentially expressed on hematopoietic stem 
cells and mediates stem cell differentiation and proliferation. Interaction of the Flt3 receptor 
with Flt3 ligand causes receptor dimerization, leading to the activation of the receptor 
tyrosine kinase and receptor autophosphorylation. The phosphorylated Flt3 transduces 
activation signals through associations with various cytoplasmic proteins, including ras 
GTPase-activating protein, phospholipase C, and Src family tyrosine kinases. Activation of 
the Flt3 receptor by ligand-dependent phosphorylation induces cellular proliferation via 
activation of cytoplasmic mediators. Thus, constitutive activation of the Flt3 pathway may 
lead to disease proliferation and may block cellular apoptotic response to conventional 
chemotherapy. An internal tandem duplication of the juxtamembrane (JM) domain-coding 
sequence of the FLT3 (FLT3-IT) gene on chromosome 13 has been identified in a group of 
patients with AML. Constitutive activation of the Flt3 receptor tyrosine kinase, either by 
internal tandem duplication (ITD) mutations of the juxtamembrane domain or point 
mutations clustering in the second tyrosine kinase domain (TKD mutations as D835), has 
been found in 20% to 30% of patients with AML and in 30% to 45% of patients with normal 
karyotype (reviewed by Stirewalt and Radich (2003)). ITD mutations have been associated 
with an increased risk of treatment failure after conventional chemotherapy (overall 
survival and disease-free survival were worse for ITD positive patients versus FLT3 
wildtype patients), whereas the prognostic relevance of FLT3 point mutations is less evident 
(D835 mutants did not appear to have a worse median overal suvival or disease-free 
survival compared with the wildtype group) (Sheikhha et al., 2003). Recently, Spassov et al 
analyzed for WT1 and FLT3-internal tandem duplication (FLT3-ITD) expression in 30 
samples of AML patients and determined that high WT1 expression correlated with the 
presence of FLT3-ITD (P = 0·014) and with a lower rate of complete remissions (P = 0·023) 
(Spassov et al., 2011). The detection of both molecular markers (WT1 and FLT3-ITD) may be 
helpful in defining high risk AML patients that need special therapeutic strategies. 
 Several studies described that a higher mutational load as determined by calculation of 
FLT3-ITD/FLT3 wildtype ratio indicates a worse prognosis in mutation carriers. Therefore, it 
was suggested that not the FLT3-ITD per se, but more likely loss of heterozygosity is 
associated with the unfavorable outcome in FLT3-ITD mutated AML (Meshinchi et al., 2001; 
Yanada et al., 2005; Thiede et al., 2002; Schnittger et al., 2011). 
2.7 EVI1 overexpression 
The ectopic viral integration site 1 (EVI1), located in chromosome 3q26, has been recognized 
in the last years as one of the most aggressive oncogenes associated to human leukemia 
(Gröschel et al., 2010). The inappropriate expression of EVI1 in hematopoietic cells has been 
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implicated in the development or progress of myeloid disorders (Lugthart et al., 2008). 
Previous studies, applying microarray technology, indicate that high levels of EVI1 
expression are detected in 10% -22% of patients with AML (Barjesteh et al., 2003). Although 
the higher expression of EVI1 gene was clearly associated with myeloid malignancies, is not 
restricted to this group. It is noteworthy that overexpression of EVI1 was also observed in 
13.8% of patients with acute lymphoid leukemia. The correlation between overexpression of 
EVI1 in bone marrow and poor outcome in AML is a frequent issue of discussion in the 
literature (Lugthart et al., 2008; Luzardo et al., 2007).  
We analyzed the incidence of EVI1 overexpression in haematological malignancies and its 
value as a prognostic factor. EVI1 overexpression (EVI1+) was examined by RT-PCR in bone 
marrow and/or peripheral blood samples of 113 AML patients at diagnosis and during 
follow-up. We found that 23.8% of AML overexpressed EVI1, as established by our 
previously determined cut-off point. Correlation with FAB subtypes stands as follows: 2M0, 
1 M1,3 M2, 6 M4, 7 M5, 1 M6, 4 secondary AML and 3 not labeled. Survival curves in the 
AML group didn´t show any significant differences in overall survival and disease free 
survival when comparing EVI1+ to EVI1- populations. In AML samples a greater than 
expected incidence of EVI1 expression was observed (22.8% vs 11% previously described). 
When survival curves were analyzed in the AML group with ages ranging from 14 to 60 
years, all of them treated with similar chemotherapy schemes, no significant difference was 
observed. However, a recent collaboration with other groups, showed that EVI1 
overexpression is a poor prognostic marker in patients <65 years in an independent large 
cohort, and showed that the total absence of EVI1 expression has a prognostic impact in the 
outcome of acute myeloid leukemia patients (Vazquez et al.,2011). 
2.8 BAALC AND MN1 
The Brain and Acute Leukemia Cytoplasmic (BAALC), human gene located on chromosome 
8q22.3, has also been found to be an important adverse prognostic factor if overexpressed in 
normal karyotype AML, suggesting a role for BAALC overexpression in acute leukemia. 
This gene is highly conserved in mammals. Normally, BAALC is almost exclusively 
expressed in neuroectoderm-derived tissues. Though little is known about the biological 
function of BAALC, it is highly expressed in hematopoietic precursor cells as well as 
leukemic blasts and is down-regulated during differentiation. BAALC has been postulated 
to play its role in the cytoskeleton network due to its cellular location. BAALC expression is 
an independent adverse prognostic factor and is associated with a specific gene-expression 
profile. Recent studies revealed the prognostic impact of BAALC expression in AML and 
also as a marker in minimal residual disease. Currently, determination of BAALC 
expression is performed by qualitative and quantitative real-time PCR, although the lack of 
validation or standardization studies limits its utility (Tanner et al., 2001; Gregory et al., 
2009; Baldus et al., 2003;  Najima et al., 2010).  
The meningioma 1 (MN1) gene is localized on human chromosome 22.  MN1 overexpression 
is a prognostic marker in patients with AML with normal karyotype characterized by an 
intermediate prognosis. Patients with high MN1 expression had a significantly worse 
prognosis (the overall survival was shorter and relapse rate was higher in this group 
compared to low MN1 expression group). High MN1 expression has as well been associated 
with other AML characteristics like inv(16) or overexpression of EVI-1 (Heuser et al, 2007). 
In addition, MN1 is able to induce myeloid leukemias in a murine model (Heuser et al, 
2011). This suggested that MN1 may play a functional role in the pathogenesis of AML. 
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We performed a retrospective analysis of MN1 expression in a group of 49 AML patients with 
a mean age of 52 years (43 de novo AML and 6 secondary AML). In order to analyze response 
to chemotherapy, overall survival and correlation to other molecular markers (NPM1, FLT3-
ITD, EVI1 and BAALC), patients were further classified into three groups depending on 
prognosis (favourable with 11 patients, intermediate with 25 and poor with 12). We analysed 
by real-time PCR the expression of MN1 in patients samples. We used as positive control of 
expression RNA of KG1 cell line that overexpress MN1. The incidence of MN1 overespression 
was 65.3%. The study showed that MN1 overexpression correlated to BAALC expression. We 
did not find relation with other markers, such as EVI-1, NPM-1 and FLT3. MN1 and BAALC 
overexpression have been associated to induction treatment refractoriness. However, due to 
the limited sample size in our series, determining whether MN1 or BAALC were actually 
involved with refractoriness was not possible. The 2-year overall survival was 52% and 53% 
for MN1 overexpressed and MN1  not overexpressed patients respectively. The 5-year overall 
survival was 52% and 42% respectively, showing no significant differences. Survival analysis 
for the intermediate risk AML group did not show significant differences either. MN1 
overexpression was not associated with a worse prognosis in any of the studied patients, 
probably due to a small sample size (Rodriguez et al., 2010). 
2.9 WT1 
The Wilms' tumor locus was identified as a tumor suppressor gene, which is inactivated in 
Wilms' tumor, a pediatric kidney cancer. This protein, displaying characteristic features of a 
transcription factor, and with an expression restricted to kidney and haematopoetic cells, was 
called Wilms' tumor gene 1 (WT1). This gene is located on chromosome 11p13 and encodes a 
zinc-finger transcription factor influencing the expression of several growth factors and their 
corresponding receptors. It is also known to be involved in the early stage of hematological cell 
differentiation. Aberrant expression may be one mechanism by which the normal function of 
WT1 is disrupted. However, the exact role of WT1 in hematopoiesis and leukemogenesis still 
remains unclear. The abundant overexpression of WT1 in leukemia creates a very attractive 
target for quantitative MRD studies in AML, especially in those samples with no specific 
fusion gene available. The method used to determine the expression of WT1 gene is the RT-
PCR, which will reveal its value as a marker to detect minimal residual disease (Keilholz et al., 
2005; Weisser et al., 2005; Inoue et al., 1994; Garg et al., 2003).  
Mutations of the coding region (most frequenly in 7 and 9 exons) of the WT1 gene have also 
been described and occur in 10–15% of AML (figure 3). Gaidzik et al. concluded that WT1 
mutation as a single molecular marker did not have an impact on outcome. On the other 
hand, Hou et al. demostrated that WT1 mutations disappeared in WT1-mutated studied 
patients who achieved complete remission, suggesting its potential use as MRD marker 
(Gaidzik et al., 2009; Hou et al., 2010).  
 
 
Fig. 3. Structure of the WT1 gene and localization of the 87 mutations identified by Gaidzik 
et al. 
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2.10 MLL rearrangement and MLL-PTD 
The MLL (mixed lineage leukemia) gene located at 11q23, is fused to a variety of partner 
genes through chromosomal translocations in acute leukemias. Up to now, more than 40 
different MLL partner genes have been identified. MLL gene contains 100 kb of DNA, but 
nearly all breakpoints are clustered within a 8.3 kb region. Molecular analysis shows that 
fusion of the amino terminus of MLL to the carboxy terminus of partner genes generates 
the critical leukemogenic fusion proteins. Abnormalities of the mixed-lineage leukemia 
(MLL) gene can be detected in de novo acute myeloid leukemia (AML) and acute 
lymphoblastic leukemia (ALL) as well as in therapy-related AML, particularly after 
treatment with DNA topoisomerase II inhibitors (generally less than 5–10% of patients 
carried this rearrangements).The most common translocation involving 11q23 in acute 
myeloid leukemia (AML) is t(9;11)(p22;q23), which results in the generation of a fusion 
transcript of MLL-AF. The other common translocations involving 11q23 in AML are 
t(6;11)(q27;q23), t(10;11)(p12;q23), t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3); these 
translocations result in the generation of fusion transcripts MLL-AF6, MLL-AF10, MLL-
ELL or MLL-ENL, respectively. In AML, MLL-AF9 has generally been associated with a 
more favourable outcome although this finding is controversial. This rearrangement is 
related to a superior event-free and overall survival as compared to patients with other 
chromosomal abnormalities or with no detectable rearrangements (Dimartino et al., 1999; 
Balgobind et al., 2005). In contrast, the other traslocation involving Cr 11q23 are asociated 
with poor prognostic in more cases (Dimartino et al., 1999; Balgobind et al., 2005). 
t(9;11)(p22;q23) is classified as intermediate and t(v;11)(v;q23) as adverse prognostic 
group (Döhner et al., 2010). Therefore, detection and identification of the different types of 
MLL rearrangements is of clinical importance. A recent study indicated that quantification 
by RQ-PCR of the fusion gene transcript levels at diagnosis may be of prognostic 
relevance (Shih et al., 2006; Jansen et al., 2005). One type of MLL rearrangement not 
detectable by classic cytogenetic is the partial tandem duplication of MLL (MLL-PTD). 
This rearrangement results most commonly from a duplication of a genomic region 
encompassing either MLL exons 5 through 11 or MLL exons 5 through 12 that is inserted 
into intron 4 of a full-length MLL gene, thus fusing introns 11 or 12 with intron 4. At a 
transcriptional level, this results in a unique in-frame fusion of exons 11 or 12 upstream of 
exon 5. In adult de novo AML with a normal karyotype, the presence of the MLL-PTD has 
been associated with a worse prognosis (ie, shorter duration of remission) when 
compared with normal karyotype AML without the MLL-PTD (Whitman et al., 2005). 
2.11 Other molecular markers in research: Renin expression 
There have been reports of experimental findings that relate the renin-angiotensin system 
(RAS) with hematopoiesis. Some studies have identified RAS components located in the 
bone marrow (Haznedaroglu & Buyukasik, 1997) that might functionally affect cellular 
proliferation and differentiation in physiological or pathological states (Huckle & Earp, 
1994; Comte et al., 1997). It has been demonstrated that the RAS component renin is 
expressed in the bone marrow microenvironment as well as in hematopoietic cells (Abali et 
al., 2002). Bone marrow blast cells of some types of AML (M4 and M5 FAB types) express 
renin (Wulf et al., 1998), however no expression has been detected in normal bone marrow 
from healthy donors (Gómez Casares et al., 2002).  Our group also detected renin expression 
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in AML patients, but it did not relate to monocytic dififerentiation or to the existence of 
other cytogenetic risk markers (Gómez Casares et al., 2002). Moreover,  renin expression has 
been found to be related to disease activity, disappearing with AML remission and 
returning with relapse (De la Iglesia et al., 2006).   
We did not found statistically significant differences in the outcome between renin-positive 
and renin-negative patients (De la Iglesia et al., 2006).   
 
 
Fig. 4. Renin:glucuronidase ratios vs clinical state of the quantified patients. *This data 
belong to third relapse, CR and fourth relapse, respectively. **This patient did not reach CR, 
continuing the positivity of the renin gene expression. ***Patient 28 in morphological CR 
was presented with 1% blasts in BM that later disappeared (De la Iglesia et al., 2006).   
 
 
Fig. 5. (a) Overall survival of renin-positive and renin-negative patients with AML. Kaplan-
Meier plot showing the correlation between overall survival and renin expression in AML 
patients. (b)Disease-free survival of renin-positive and renin-negative patients with AML. 
Kaplan-Meier plot showing the correlation between disease-free survival and renin 
expression in AML patients. (De la Iglesia et al., 2006).   
Renin expression is related to undifferentiated phenotypic cell lines (K562, KU812), since 
no expression of the renin gene was found in cellular lines that showed a highly 
differentiated phenotype like HL60 and U937 (Gómez Casares et al., 2002). ACE inhibitors 
(captopril and trandolapril) and AT1 receptor blocker (losartan) produce a stop in 
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proliferation  in K562 cells with captopril (C) 10 mM and trandolapril (T) 2 mM (figure 6a) 
as well as an increase in the apoptotic rate in renin positive leukemia cell lines (K562) after 
the treatment with captopril (data not shown) and trandolapril (figure 6b) (De la Iglesia et 
al., 2009).  
 
 
 
 
 
 
Fig. 6. (a) Proliferation in K562 after the treatment with captopril (C) and trandolapril (T). (b) 
C-myc gene expression in K562 after the treatment with the same drugs. (c) Apoptosis 
determined by annexin V binding in K562 and K562 transfected with bcl-2 and bcl-x (Kbcl2 
and Kbclx) cells treated with 1mM trandolapril (T) (De la Iglesia et al., 2009). All 
experiments were performed in triplicate. 
The leukaemogenic role of renin gene expression and the implicated molecular pathways 
have not yet been elucidated but it may offer novel therapeutic approaches in pathological 
or neoplastic conditions (Haznedaroglu & Öztürk, 2003). 
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3. Conclusion 
The AML embraces very heterogeneous entities with different clinical behaviours. Some of 
these leukemias have certain chromosomal alterations that are related to specific 
morphological and clinical subtypes. Their identification has had great impact on different 
management aspects of these diseases, either from the standpoint of diagnosis, prognosis or 
development of a treatment plan tailored to the risk of relapse. This has been largely 
possible thanks to the application of molecular biology studies, which have provided a 
better and deeper understanding of the pathogenesis of leukemia. 
The genetic alterations that occur at different stages fall into two broad groups: those that 
activate signal transduction as c-KIT and FLT3 (type I) and those which alter transcription 
factors such as CBF, RAR-, CEBPA and NPM1 (type II). These two groups work together in 
leukemogenesis, being very frequent the coexistence of alterations of the two groups in the 
same patient. 
The knowledge of these molecular markers helps us to classify patients within certain 
prognostic groups.  In this way, in patients with normal cytogenetics, it is very important to 
know if there is a mutation of the FLT3 gene as well as its kind (ITD or TKD), because this 
information is of great relevance in order to select the appropriate treatment scheme. 
Moreover, the overexpression of the genes BAALC (under OS, DFS), MN1 (induction failure 
in patients with normal karyotype) or EVI1 (adverse impact) has been shown to have 
prognostic significance in AML. 
In a laboratory setting there are different ways to classify leukemias. One of them is the 
rationale showed in the figure 5. According to the cytogenetic or molecular biology at 
diagnosis, it is possible to perform different determinations which will allow us to classify 
the patients within a favourable or unfavourable prognostic group. AML patients are 
classified at the time of diagnosis into three different prognostic groups based on their 
cytogenetic profiles. 
There are plenty of algorithms which allow us to classify patients into different prognostic 
groups. They are undergoing continuous changes with the enrichment of new data. If we 
are in the presence of a CBF leukemia (by showing RUNX1-RUNXT1 or inv (16)), mutational 
analysis of c-kit should be performed, as this mutation translates into a higher risk of 
relapse. In patients with AML with normal karyotype, we recommend to analyze for FLT3-
ITD first, as FLT-ITD3 is a well-known adverse prognostic factor. We then recommend 
screening for NPM1 mutations as a next step, because it is another mutation with clinical 
relevance of this subgroup of patients in the absence of FLT3-ITD. Then, given the 
favourable prognosis of NK-AML with biallelic CEBPA mutation, we recommend a CEBPA 
mutational analysis in those patients non-carriers of FLT3-ITD or NPM1. Also,  FLT3-TKD 
an others mutations can be analyze in a context of clinical trials, even though there is no 
prognostic relevance. 
There after, it is possible to perform other studies such as the detection of mutations in 
MLL/AF9 or BAALC, MN1 and EVI1 gene overexpression in order to make a better 
stratification of the prognosis. Besides working with prognostic and follow up markers with 
a recognized utility, we are also carrying out experimental work with new, not yet validated 
markers which will probably help us in the follow up, prognosis, classification and 
monitoring of AML patients. Renin, EVI1 and WT1 would be markers applicable to AML 
patients, especially in those with normal karyotype where they will facilitate the monitoring 
of minimal residual disease.  
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GENETIC GROUP SUBSET 
 
Favorable  
 
 
t(8;21)(q22;q22); RUNX1-RUNX1T1 
inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
Mutated NPM1 without FLT3-ITD (normal karyotype) 
Mutated CEBPA (normal karyotype) 
 
 
Intermediate-1 
 
 
Mutated NPM1 and FLT3-ITD (normal karyotype) 
Wild-type NPM1 and FLT3-ITD (normal karyotype) 
Wild-type NPM1 without FLT3-ITD (normal karyotype) 
 
Intermediate-2 
 
 
t(9;11)(p22;q23); MLLT3-MLL 
Cytogenetic abnormalities not classified as favorable or 
adverse 
 
Adverse 
 
 
inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
t(6;9)(p23;q34); DEK-NUP214 
t(v;11)(v;q23); MLL rearranged 
-5 or del(5q); -7; abnl(17p); complex karyotype 
 
Table 5. Standardized reporting for correlation of cytogenetic and molecular genetic data in 
AML with clinical data (Döhner. European LeukemiaNet , 2010) 
In recent past, treatments had an empirical basis, lack of specificity and, therefore, limited 
effectiveness combined with high toxicity. The treatment of AML pioneered the search for 
specific therapies with the use of ATRA in APL. Currently, the ultimate goal of the 
understanding and classification of molecular aberrations in every AML subtype is to 
design a targeted therapy, which will reduce the risk of relapse and treatment side effects. 
That is because the future of AML therapy should be in the search and development of 
drugs that are directed against specific molecular or fusion proteins aberrations. On the 
other hand, due to the interaction between different molecular aberrations that arise in 
AML, the design of these new drugs has to be focused on the combined inhibition of several 
signalling pathways to achieve maximum clinical benefit. 
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